[go: up one dir, main page]

EA200702361A1 - АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ - Google Patents

АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ

Info

Publication number
EA200702361A1
EA200702361A1 EA200702361A EA200702361A EA200702361A1 EA 200702361 A1 EA200702361 A1 EA 200702361A1 EA 200702361 A EA200702361 A EA 200702361A EA 200702361 A EA200702361 A EA 200702361A EA 200702361 A1 EA200702361 A1 EA 200702361A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cspcna
isoforms
application
antibodies against
isoform
Prior art date
Application number
EA200702361A
Other languages
English (en)
Inventor
Роберт Дж. Хикки
Линда Х. Малкас
Лорен Шнапер
Original Assignee
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн
СиЭс-КИЗ, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн, СиЭс-КИЗ, ИНК. filed Critical Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн
Publication of EA200702361A1 publication Critical patent/EA200702361A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Антитела специфически связываются лишь с раковой специфической изоформой ядерного антигена пролиферирующих клеток (csPCNA), но не связываются с незлокачественной изоформой ядерного антигена пролиферирующих клеток (nmPCNA). Раскрываются способы и композиции для выявления присутствия csPCNA изоформы.
EA200702361A 2005-04-27 2006-04-27 АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ EA200702361A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67527505P 2005-04-27 2005-04-27
US68961405P 2005-06-09 2005-06-09
PCT/US2006/016096 WO2006116631A2 (en) 2005-04-27 2006-04-27 Cancer specific pcna isoform binding antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EA200702361A1 true EA200702361A1 (ru) 2008-04-28

Family

ID=37215524

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702361A EA200702361A1 (ru) 2005-04-27 2006-04-27 АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ

Country Status (9)

Country Link
US (4) US20080206140A1 (ru)
EP (1) EP1874823B1 (ru)
JP (1) JP2008539271A (ru)
AU (1) AU2006239318A1 (ru)
BR (1) BRPI0607676A2 (ru)
CA (1) CA2605745A1 (ru)
EA (1) EA200702361A1 (ru)
MX (1) MX2007013584A (ru)
WO (1) WO2006116631A2 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294471B2 (en) * 2002-02-27 2007-11-13 Cskeys, Llc Method for purifying cancer-specific proliferating cell nuclear antigen
US8653039B2 (en) 2006-02-17 2014-02-18 Robert J. Hickey Peptide based inhibition of caPCNA interaction in cancer
CA3023068C (en) 2008-07-24 2022-06-21 Indiana University Research And Technology Corporation Cancer peptide therapeutics
US20120195978A1 (en) * 2009-10-07 2012-08-02 Indiana University Research And Technology Corpora Capcna peptide therapeutics for cancer
US8455200B2 (en) 2009-10-15 2013-06-04 Traxxsson, Llc Measurement of PKA for cancer detection
EP2688566A4 (en) * 2011-03-23 2014-09-10 Univ Indiana Res & Tech Corp THERAPEUTIC AGENTS AGAINST CANCER
US10451633B2 (en) 2014-03-24 2019-10-22 IMMCO Diagnostics, Inc. Anti-nuclear antibody detection and diagnostics for systemic and non-systemic autoimmune disorders
US10420840B2 (en) 2015-04-10 2019-09-24 Rll, Llc Anticancer therapeutic agents
KR20190091483A (ko) 2016-12-15 2019-08-06 더 내셔널 인스티튜트 포 바이오테크놀로지 인 더 네게브 엘티디. 항-pcna 단클론성 항체 및 이의 용도
MA52889A (fr) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU750082B2 (en) * 1997-09-29 2002-07-11 University Of Maryland At Baltimore Altered DNA synthesome components as biomarkers for malignancy
US7294471B2 (en) * 2002-02-27 2007-11-13 Cskeys, Llc Method for purifying cancer-specific proliferating cell nuclear antigen
ATE401575T1 (de) * 2003-01-06 2008-08-15 Wyeth Corp Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
CN101632020B (zh) * 2006-09-13 2013-11-27 昂西免疫有限公司 改进的免疫测定方法

Also Published As

Publication number Publication date
US20080206140A1 (en) 2008-08-28
AU2006239318A8 (en) 2006-11-02
EP1874823A2 (en) 2008-01-09
BRPI0607676A2 (pt) 2009-09-22
CA2605745A1 (en) 2006-11-02
US9006396B2 (en) 2015-04-14
WO2006116631A2 (en) 2006-11-02
US20120244076A1 (en) 2012-09-27
JP2008539271A (ja) 2008-11-13
WO2006116631A3 (en) 2007-03-22
MX2007013584A (es) 2008-04-22
HK1110338A1 (zh) 2008-07-11
US20180362626A1 (en) 2018-12-20
AU2006239318A1 (en) 2006-11-02
EP1874823B1 (en) 2016-01-13
US20150259407A1 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
EA200702361A1 (ru) АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ
EA200970210A1 (ru) Prlr-специфическое антитело и его применения
CY1122210T1 (el) Ανθρωπινα αντισωματα anti-sod1
CY1123518T1 (el) Ανθρωπινα αντισωματα enanti-tau
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
PH12016500658A1 (en) Human anti-alpha-synuclein autoantibodies
EA201270654A1 (ru) Моноклональные антитела, связывающие b7h6, и их применение
IN2009KN02404A (ru)
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
MX2018005512A (es) Agentes de union de esclerostina.
CL2008002085A1 (es) Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
CY1117942T1 (el) Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april)
MX2009003306A (es) Anticuerpos humanos que se unen a cxcr4 y sus usos.
BRPI0607323B8 (pt) composições, usos de polipeptídeos e de anticorpos, bem como kits para a detecção de anticorpo que se liga especificamente a um polipeptídeo
MX2018008680A (es) Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).
BR112013010213A2 (pt) anticorpos que unem ligantes solúveis de receptores de célula t
TR201808535T4 (tr) İki veya daha fazla sayıda antijen molekülüne tekrar tekrar bağlanabilen antijen bağlanma molekülü.
EA201100779A1 (ru) Композиции антител к cxcr1 и способы их применения
BRPI0812488A2 (pt) Anticorpos anti-cd44 humanizados e quiméricos que mediam citotoxidade de célula de câncer, usos dos mesmos, ensaios de ligação, métodos, composições e kit de ensaio
MA33276B1 (fr) Anticorps spécifiques à la cadhérine-17
EA200801847A1 (ru) ПЕПТИДНОЕ ИНГИБИРОВАНИЕ ВЗАИМОДЕЙСТВИЯ caPCNA ПРИ РАКЕ
MA33210B1 (fr) Nouveaux anticorps anti-a5b1 et leurs utilisations
MX2009005103A (es) Conjugado anti-idiotipo y su uso como un estandar en un inmunoensayo.
NO20083609L (no) Fremgangsmater og sammensetninger for malrettet-RELT
EA200800144A1 (ru) МОДИФИКАЦИИ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ